Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CSD500 is an erectogenic condom developed by Futura Medical and licensed to Reckitt Benckiser for sale under the Durex brand, most notably as Durex Blue Diamond. The product is a medical device that incorporates a proprietary vasodilator gel called Zanifil, which contains the active ingredient glyceryl trinitrate (nitroglycerin), within the tip of the condom. Upon application, the gel is absorbed through the skin of the penis, acting as a nitric oxide donor to stimulate local vasodilation and increase blood flow. This mechanism is designed to help men maintain firmer, larger, and longer-lasting erections during intercourse, potentially encouraging condom use for contraception and the prevention of sexually transmitted infections. CSD500 has received CE mark approval in Europe and is marketed in several regions, including the Middle East and North Africa.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CSD500.